AZD 2066 single dose formulation and food effect study in healthy volunteers

Study identifier:D0475C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1, single-center, randomized, open-label, two-way crossover, formulation and food effect study in healthy volunteers, to assess the pharmacokinetics of AZD 2066 after single doses of a new oral solid formulation and an oral solution

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2066

Sex

All

Actual Enrollment

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Apr 2008

Primary Completion Date: 01 Jun 2008

Study Completion Date: 01 Jun 2008

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1	Drug: AZD2066 single oral dose

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1638&filename=CSR-D0475C00005.pdf
Download
CSR-D0475C00005.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

800-369-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Eleanor Lisbon

Quintiles, Inc. Overland Park, Kansas, USA